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Video Game Rehabilitation for Outpatient
Stroke (VIGoROUS): protocol for a multicenter comparative effectiveness trial of inhome gamified constraint-induced
movement therapy for rehabilitation of
chronic upper extremity hemiparesis
Lynne V. Gauthier1* , Chelsea Kane1, Alexandra Borstad2, Nancy Strahl3, Gitendra Uswatte4, Edward Taub4,
David Morris5, Alli Hall1, Melissa Arakelian3 and Victor Mark4,6,7

Abstract
Background: Constraint-Induced Movement therapy (CI therapy) is shown to reduce disability, increase use of the
more affected arm/hand, and promote brain plasticity for individuals with upper extremity hemiparesis post-stroke.
Randomized controlled trials consistently demonstrate that CI therapy is superior to other rehabilitation paradigms,
yet it is available to only a small minority of the estimated 1.2 million chronic stroke survivors with upper extremity
disability. The current study aims to establish the comparative effectiveness of a novel, patient-centered approach
to rehabilitation utilizing newly developed, inexpensive, and commercially available gaming technology to disseminate
CI therapy to underserved individuals. Video game delivery of CI therapy will be compared against traditional clinicbased CI therapy and standard upper extremity rehabilitation. Additionally, individual factors that differentially influence
response to one treatment versus another will be examined.
Methods: This protocol outlines a multi-site, randomized controlled trial with parallel group design. Two hundred
twenty four adults with chronic hemiparesis post-stroke will be recruited at four sites. Participants are randomized to
one of four study groups: (1) traditional clinic-based CI therapy, (2) therapist-as-consultant video game CI therapy, (3)
therapist-as-consultant video game CI therapy with additional therapist contact via telerehabilitation/video
consultation, and (4) standard upper extremity rehabilitation. After 6-month follow-up, individuals assigned to the
standard upper extremity rehabilitation condition crossover to stand-alone video game CI therapy preceded by a
therapist consultation. All interventions are delivered over a period of three weeks. Primary outcome measures include
motor improvement as measured by the Wolf Motor Function Test (WMFT), quality of arm use for daily activities as
measured by Motor Activity Log (MAL), and quality of life as measured by the Quality of Life in Neurological Disorders
(NeuroQOL).
(Continued on next page)
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Discussion: This multi-site RCT is designed to determine comparative effectiveness of in-home technology-based
delivery of CI therapy versus standard upper extremity rehabilitation and in-clinic CI therapy. The study design also
enables evaluation of the effect of therapist contact time on treatment outcomes within a therapist-as-consultant
model of gaming and technology-based rehabilitation.
Trial registration: Clinicaltrials.gov, NCT02631850.
Keywords: Protocol, Research design, Randomized controlled trial, CI therapy, Constraint-induced movement therapy,
Rehabilitation, Video game, Stroke, Virtual reality, Motor, Hemiparesis

Background
Clinical practice guidelines recommend outpatient rehabilitation for stroke survivors who remain disabled after
discharge from inpatient rehabilitation [1]. Although these
guidelines recommend that the majority of stroke survivors
receive at least some outpatient rehabilitation [2], many
cannot access long-term care [3]. Among those individuals
who do undergo outpatient rehabilitation, the standard of
care for upper extremity rehabilitation is suboptimal.
In an observational study of 312 rehabilitation sessions (83
occupational and physical therapists at 7 rehabilitation sites),
Lang and colleagues [4] found that functional rehabilitation
(i.e., movement that accomplishes a functional task, such as
eating, as opposed to strength training or passive movement)
was provided in only 51% of the sessions of upper extremity
rehabilitation, with only 45 repetitions per session on average. This is concerning given that empirically-validated interventions incorporate higher doses of active motor practice
[5–7]. Additionally, functional upper extremity movements
are most likely to generalize to everyday tasks [8], an aspect
of recovery that is critically important to patients and their
families [9–11]. Yet, passive movement and non-goaldirected exercise are more frequently administered [4].
There appear to be at least two critical elements
required for successful upper extremity motor rehabilitation: 1) motor practice that is sufficiently intense and 2)
techniques to carryover motor improvements to functional activities. Carry-over techniques to increase a person’s use of the more affected upper extremity for daily
activities are extremely important for rehabilitation and
appear necessary for structural brain change [12–15].
When rehabilitation incorporates these techniques, there
is substantially improved improvement in self-perceived
quality of arm use for daily activities [12, 16]. Carry-over
techniques enable the patient to overcome the conditioned suppression of movement (learned nonuse) characteristic of chronic hemiparesis [17]. Techniques
include structured self-monitoring, a treatment contract,
daily home practice of specific functional motor skills,
and guided problem-solving to overcome perceived
barriers to using the extremity [18].
Constraint-Induced Movement therapy (CI therapy) has
strong empirical backing [5, 19] and combines high-

repetition functional practice of the more affected arm
with behavioral techniques to enhance carry-over [13, 18].
CI therapy produces consistently superior motor performance and retention of gains versus standard upper extremity rehabilitation [20, 21], particularly when it includes the
critically important carry-over (transfer package) techniques [12]. When compared to other equally intensive
interventions (i.e., equal hours of training on functional
tasks), CI therapy with carry-over (transfer package) techniques has also shown enhanced carry-over of clinical
gains to daily activities [12, 13, 22–24] that are retained
for at least 2 years [19, 25–28].
Despite its inclusion in best practice recommendations
[29, 30], CI therapy is available to only a very small minority of those who could benefit from it in the US. CI therapy
is not typically covered by insurance and the 30+ hours of
assessment and physical training cost upwards of $6000.
Access barriers for the patient include limited transportation and insurance coverage, whereas therapists may have
difficulty accommodating the CI therapy schedule [31, 32].
Access barriers aside, CI therapy has also been plagued by
a variety of misconceptions regarding use of restraint and
the transfer package. Most iterations of CI therapy employ
use of a restraint mitt to promote use of the affected arm,
which is viewed by many patients and clinicians as excessively prohibitive [32]. Yet, literature demonstrates that
restraint is not specifically required to achieve positive outcomes [33, 34]. Moreover, the transfer package, a component found to be critical [13, 14], is omitted from the
majority of research studies on CI therapy [35].
To address transportation barriers, a telerehabilitation
model of CI therapy delivery (AutoCITE) has been tested.
AutoCITE is a large specialized motor apparatus (not
commercially available, cost not established) that was
installed in patients’ homes to enable therapeutic manipulation of actual objects with continuous video monitoring
via Internet. This telerehabilitation approach demonstrated efficacy approximately equivalent to that of inclinic CI therapy [36–38], thus establishing the feasibility
of utilizing technology to deliver CI therapy remotely.
However, this system involved specialized equipment at a
high cost and did not become available outside a research
setting.
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To more fully address the barriers to accessing CI therapy and to counter the misconceptions surrounding CI
therapy, a patient-centered treatment approach was developed that incorporated the high-repetition practice and
carry-over strategies from CI therapy, while reforming
non-patient-centric elements of the protocol that lack
strong empirical support (i.e., the restraint). To deliver engaging high-repetition practice, a Kinect-based video game
was created that can accommodate a wide range of motor
disability, can be customized to each user, and automatically progresses in difficulty as the individual’s performance
improves (termed “shaping” in the CI therapy literature).
A player’s body movements drive game play (there is no
external controller), which makes the game easy to use for
those who may be unfamiliar with technology. To date,
such high-repetition practice through motor gaming [39]
has shown initial promise compared to traditional clinicbased approaches [40]. To promote increased use of the
weaker arm, a smart watch biofeedback application is utilized in lieu of the restraint mitt. This application counts
movements made with the weaker arm and provides alerts
when a period of inactivity is detected. Previous approaches for providing CI therapy in the home and reducing the amount of therapist effort have been carried out
[36–38, 41]. These approaches automated the delivery of
training and permitted remote supervision of the training
via an Internet-based audio-visual link, but did not embed
the training within the context of a video game, rely on
manipulation of virtual objects, or incorporate a patientcentric substitute for the mitt.
Initial evidence from a pilot trial of this system (Borstad
A, Crawfis R, Phillips K, Pax Lowes L, Worthen-Chaudhari
L, Maung D, et al.: In-home delivery of constraint induced
movement therapy via virtual reality gaming is safe and
feasible: a pilot study, submitted) suggests that improvements in motor speed, as measured by Wolf Motor Function Test (WMFT) performance time [42], an outcome of
prime importance to stroke survivors, are approximately
equivalent to those reported in the traditional CI therapy
literature [5, 13, 19, 25]. Qualitative data reveal that the
technology is accepted irrespective of age, technological expertise, ethnicity, or cultural background. Thus, this technology has the potential to address the main barriers to
adoption of CI therapy, while reducing the cost of care. A
randomized clinical trial is now required to provide Level 1
evidence of the comparative effectiveness of this novel
model of CI therapy delivery. Data from this trial will enable individuals with motor disability to evaluate whether a
home-based video game therapy has the potential to help
them meet their rehabilitation goals compared to in-clinic
CI therapy and traditional approaches. By combining novel
gaming elements with the transfer package from CI therapy, this trial will also address a major limitation of rehabilitation gaming interventions that have been tried to
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date: extremely limited emphasis on carry-over of training
to daily activities.
The primary objective of this trial is to compare the effectiveness of two video game-based models of CI therapy versus traditional clinic-based CI therapy versus
standard upper extremity rehabilitation for improving
upper extremity motor function. One video gaming
group will match the number of total hours spent on the
CI therapy transfer package, but will involve fewer days
of therapist-client interaction (4 versus 10); the other
will match the number of interactions with a therapist to
that of clinic-based CI therapy using video consultation
between in-person sessions and, as such, will involve
more therapist contact hours spent focusing on the
transfer package. The secondary objective of this project
is to promote personalized medicine by examining individual factors that may differentially influence response
to one treatment versus another.

Methods/design
Study setting

Study screenings, interventions, and assessments are conducted at four separate sites in the United States, each an
outpatient medical facility. The four study sites include
Ohio State University (Columbus, OH), Ohio Health
(Columbus, OH), Providence Medford Medical Center
(Medford, OR), University of Alabama (Birmingham, AL).
Interventions are completed by licensed physical/occupational therapists or individuals with appropriate clinical
training (e.g., occupational therapy assistants, graduate
students) under the supervision of a licensed physical or
occupational therapist. Game-play and home-practice occurs independent of the therapist’s presence and is performed in the home environment.
Eligibility criteria
Inclusion

Broad enrollment criteria will be employed to include a
representative sample of patients with upper extremity
motor impairment. In order to be eligible to participate in
this study, an individual must meet all of the following
criteria:
 Ability to demonstrate informed consent to







participate in research (see “Informed Consent”
below).
Expressed willingness to attempt to comply with all
study procedures and attend all study-related visits.
Age ≥ 18.
Demonstrated ability to comprehend English and
participate in basic elements of the study, as
evidenced by ability to follow one-step commands.
Community-dwelling.
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 Experienced a stroke (of any etiology) resulting in

mild to moderate hemiparesis at least six months
prior (defined by criteria in Table 1).
 Can independently operate the gaming system
(those with severe cognitive impairments can usually
achieve this).
 Corrected vision of at least 20/70 as assessed by their
ability to identify game objects on the monitor from
5 ft away.
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treatments or make intensive rehabilitation difficult
to tolerate. Potential participants will be given the
option to self-exclude if they have pain that would
be significantly aggravated by participation in the
protocol and would limit ability to complete treatment per protocol.
Interventions

Individuals will be enrolled irrespective of ethnicity,
gender, native language (assuming basic comprehension
of English), or mobility; thus, this work will include individuals who have historically been excluded from CI
therapy trials (e.g., wheelchair users, those with substantial cognitive impairment, those with balance impairments) to increase the generalizability of the results.
Data regarding current medication prescription and
usage is collected during the in-person screening phase.
Participants are asked to limit changes to spasticitymodifying medications during participation in the study.
Participants are asked about the use of anti-spasticity
agents during in-person screening. Participants who report receiving botulinum toxicity injections may not participate in pre-testing or intervention within 12 weeks
from the last injection, but may begin participation
12 weeks after their last botulinum toxin injection as
long as they refrain from additional Botox therapy during the study intervention phase and 12 weeks prior to
follow-up testing. If the participant is using other antispasticity agents (i.e. oral Baclofen), this information is
noted in the participant’s file but does not exclude them
from participating in the study.

An advisory board that comprises therapists, caregivers,
and stroke survivors assisted to formulate the study design. In particular, these stakeholders provided insight
into specific concerns and needs relevant to the stroke
community. The relevant questions posed by the stroke
community were: Is home-based CI therapy through
gaming as effective as in-clinic CI therapy? Can therapist
time be used more efficiently by supplementing in-clinic
practice with in-home gaming CI therapy? Will more
frequent contact with a therapist (whom they feel holds
them accountable for completing the therapy protocol)
lead to better outcomes? The below comparison groups
will address these questions using appropriate controls.
Stakeholders nearly unanimously reported preferring the
more intense and compressed treatment delivery schedule of CI therapy compared to a more distributed treatment delivery schedule, but also requested a slight
reduction in the treatment days per week from traditional CI therapy (10 days in 2 weeks) to better accommodate caregiver schedules. Thus, all interventions
occur over a 3 week period. A target of 224 participants
will be randomized to one of four intervention groups
(56 per group). See Table 5 for an overall depiction of
the study timeline, discussed in more detail in the Participant Timeline section.

Exclusion

Group 1: Traditional in-clinic CI therapy

Although CI therapy has been successfully offered (with
adaptations) for those with more severe motor impairments [43], this trial excludes these individuals because
substantial modifications to the protocol would be
required.
An individual who meets any of the following criteria
is excluded from participation in this study:

This group follows the established method of delivering
CI therapy, as documented by Morris, Taub, and colleagues [18]. Participants randomized to this group receive ten 3.5-h sessions of in-clinic traditional CI
therapy with a therapist. They agree to wear a restraint
mitt for a target of 10 h daily. Participants receive 30 h
of massed practice with shaping (50% of this time spent
in active movement) and 5 h of transfer package techniques emphasizing carry-over of motor gains to daily
activities (more detail below).
Massed motor practice with shaping occurs for 3 h
each treatment day on 10 treatment days within a 3week period. Five to nine tasks per day are administered,
each consisting of up to ten 30–120 s trials. Tasks are
selected such that they are well within a participant’s
capability, but are not optimally performed by a participant. Treatment time consists of 50% active motor practice and 50% rest/task set-up, for a target of 15 h active
motor practice over the course of the intervention.

 Concurrent participation in other experimental

upper extremity rehabilitation trials.
 Concurrent participation in other outpatient

rehabilitation for their upper extremity during the
treatment phase(s) of the study.
 Botox within 3 months prior to beginning studyrelated treatments (confound).
 Substantial use of the more-affected arm in daily life
(Motor Activity Log [MAL] score at screening >2.5).
 Major medical issues such as upcoming surgery or
procedures that would interfere with study

Extension ≥20°
from a 90° flexed
starting position

Flexion ≥90°
Abduction ≥90°
External rotation ≥45°

Flexion ≥45° and
Abduction ≥45°

Minimum active ROM

MCP metacarpophalangeal, PIP proximal interphalangeal, DIP distal interphalangeal

Elbow
Extension to ≥150°

Shoulder

Minimum passive ROM

Extension ≥10°
from fully flexed
starting position

Extension ≥0°
Forearm supination/pronation ≥45°

Wrist

Table 1 Minimum Active and Passive Range of Motion (ROM) required for participation

Extension MCP and (PIP or DIP)
joints of at least 2 fingers ≥10°

MCP extension to ≥145°

Fingers

Extension or abduction of thumb ≥10°

Extension or abduction of thumb ≥10°

Thumb

Gauthier et al. BMC Neurology (2017) 17:109
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Trial-level performance feedback (e.g., number of repetitions in a given task time, time to complete a fixed number of repetitions) is provided to the participant
following every trial. Verbal encouragement and/or
coaching is provided on at least 80% of trials. Task difficulty is shaped (progressed) systematically (e.g., when
the average of the most recent 5 trials exceeds the average of the previous 5 trials). See Shaping Procedure
document published on the PI’s ResearchGate site (link
below in Availability of Data and Materials section) for
a more detailed account of the shaping procedure.
The transfer package of carry-over techniques consists
of the following 5 elements (for more detail, see Morris,
D., Taub, E., & Mark, V. (2006) [18]).
1) Treatment Contract: Completing the Treatment
Contract takes approximately 45 min and involves
learning the elements of the intervention,
establishing a formal agreement to adhere to the
different elements of CI therapy, goal setting, and
outlining in detail which activities of daily living will
be performed exclusively with the more affected
upper extremity versus with both upper extremities
versus with the less affected upper extremity
exclusively. The participant maintains a Home
Achievement Record for daily self-monitoring of
arm use for pre-specified daily activities that are
agreed to during completion of the Treatment
Contract. Adherence to the contract is reviewed on
each of the subsequent 9 treatment days. Guided
problem-solving is carried out as necessary to
enhance use of the weaker arm for daily activities. A
Caregiver Contract provides guidance on when it is
appropriate for the caregiver to assist with ADLs
and on how to provide effective encouragement.
2) MAL: The MAL assesses the amount and quality of
upper extremity arm use for 28 activities of daily
living. The full MAL is administered on Days 1 and
6, whereas half of the MAL is administered on other
treatment days (total of 6 administrations). The
therapist uses guided problem-solving with the
participant regarding strategies to improve
functional use of the more affected upper extremity
on at least 2 items from the MAL, per
administration. The “say-do-check” problem-solving
procedure employed here is based on the work of
Skidmore and colleagues (2011) [44]. The “say-docheck” procedure emphasizes eliciting strategies
from the participant, objectively testing the
effectiveness of these strategies, and revising the plan
as needed. See Guided Problem Solving document
on ResearchGate for more detail.
3) Home Skill Assignment: Participants practice 10
functional motor tasks that are collaboratively
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agreed upon (e.g., play drums, practice golf swing,
sort silverware) for 30 min per treatment day,
beginning after the second treatment day. Activity is
recorded by the participant and is discussed with the
therapist daily.
4) The restraint mitt is worn on the less affected upper
extremity for a target of 10 h per day (both in and
outside of treatment) on all treatment days to
encourage using the more affected arm. A motion
sensor with LCD display is placed within the mitt to
provide the participant with immediate feedback on
how long the mitt was worn and to enable therapists
to monitor treatment adherence.
5) MAL in follow-up: To promote enhanced carry-over
and retention, 4 weekly teleconsultation sessions are
scheduled after treatment. These sessions involve
telephone administration of the MAL with problemsolving.
Group 2: In-home gaming CI therapy + in-clinic therapist
consultation

This group utilizes in-home gaming CI therapy in conjunction with in-clinic consultation with a therapist throughout
the intervention period. The following components of the
intervention will be included: 1) high repetition motor practice through use of game-based CI therapy, 2) a transfer
package of carry-over techniques, and 3) using smart watch
technology to promote using the more affected upper
extremity.
High repetition motor practice is achieved through inhome game play. Participants agree to play the game for
15 h over three weeks (ten treatment days; approximately
1.5 h of game play daily). Participants are encouraged to
break play into at least 3 separate play sessions per day to
allow appropriate rest. Participants are also encouraged to
complete any missed game play during “off” days. Instruction to play the game is provided for approximately 30 min
on the first treatment day. The gaming system logs play
times and they are stored on a cloud-based server to enable
the therapist to monitor treatment compliance. To enable
including participants in rural or urban areas regardless of
Internet access, participants assigned to the gaming groups
are lended mobile hotspots during the treatment period.
On subsequent days, the therapist checks participants’ adherence to game play and uses guided problem-solving to
address compliance when necessary.
Game play is driven solely by movements made with the
more affected upper extremity (Table 2). The CI therapy
principle of “shaping” is incorporated into the game, such
that movements are automatically made more difficult as
a person’s range of motion improves. For example, to
move the game character forward, the user performs a
row gesture consisting of shoulder flexion/extension with
elbow extension. The software will initially require just 30
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Table 2 Upper extremity motions corresponding to game
actions
Motion

Game action elicited

Shoulder flexion/extension with elbow
extension

Row kayak down river

Shoulder abduction with elbow extension

Steer kayak toward
hemiparetic side

Horizontal shoulder adduction across
midline

Steer kayak away from
hemiparetic side

Elbow flexion/extension

Catch fish with a net

Elbow flexion/extension and grasp/release

Collect bottles from a river

Forearm supination with shoulder flexion
and elbow extension

Catch parachute to receive
supplies

Finger flexion/extension and thumb
abduction/adduction, shoulder flexion to
position hand over target

Pick fruit from bushes

Forearm supination with shoulder flexion to Turn over card
position hand over target
Wrist extension with shoulder flexion to
position hand over target

Flick letters in word puzzle

degrees of shoulder flexion to trigger forward movement;
however, if a person is able to consistently demonstrate 60
degrees of flexion with almost full extension, the software
will require that the user perform the movement to his/
her capacity. The gaming environment is shown in Fig. 1.
The transfer package of carry-over techniques for
Group 2 includes the same elements of the transfer package
of traditional CI therapy (Treatment Contract, MAL, Home
Skill Assignment), with the exception of the mitt restraint
being replaced with a smart watch biofeedback app (see
below). Administrating the Treatment Contract and Caregiver Contract is identical to Group 1 and occurs at the beginning of the first treatment day. The Home Achievement
Record of the Treatment Contract is reviewed on each subsequent treatment visit and guided problem-solving is carried out as necessary to enhance use of the weaker arm for

Fig. 1 Screen capture of the Recovery Rapids gaming environment
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daily activities. Similarly, the Home Skill Assignment is identical to Group 1, but begins on the first treatment day.
The MAL is administered on each treatment day, but is
done so via a computer application. One half of the MAL is
completed at home by the participant on each treatment
day. When a participant reports having not engaged in an
activity, a problem-solving module is presented whereby the
participant selects a potential strategy to enhance success
from a pre-derived list of 2–3 strategies. Participant responses are stored on a cloud-based server so they can be
remotely accessed by a therapist. The therapist reviews the
MAL responses and uses guided problem-solving on at least
2 items on each subsequent treatment day. The MAL in
follow-up is administered weekly for 4 weeks via REDCap
(Research Electronic Data Capture) survey, an Internetbased data collection system (see Data Collection & Management). Participants without internet access (Hotspots are
returned at post-test) complete paper and pencil versions of
the MAL and mail them in.
Smart watch biofeedback technology is utilized to promote use of the more affected upper extremity during
daily activities in lieu of the mitt. The decision to replace
the mitt with a PebbleTimeTM smart watch app was informed by questionable importance of the mitt component of CI therapy [33, 34], poor compliance with mitt
use in a previous pilot study (Borstad A, Crawfis R,
Phillips K, Pax Lowes L, Worthen-Chaudhari L, Maung
D, et al.: In-home delivery of constraint induced movement therapy via virtual reality gaming is safe and feasible: a pilot study, submitted), and expression of a strong
preference for the app by the participants. The smart
watch app uses a tri-axial accelerometer to record the
number of movements made with the weaker arm. It
provides approximate movement counts and alerts the
user when a ten-minute period of inactivity is detected.
The smart watch is worn on the less affected arm for
2 days prior to treatment initiation to establish a target
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for use of the weaker arm. Participants are then
instructed to wear the watch on the weaker arm during
waking hours throughout the intervention and to record
their daily movement counts each evening before bed
for later review by the therapist. By doing so, participants aim to utilize their more affected arm to the same
extent during the trial as they used their less affected
arm prior to the trial.
Game-play instruction and the above carry-over techniques are carried out over 4 therapist consultation sessions. In-person consultations occur approximately on days
1, 3, 5, 8. The initial consultation is 2 h and involves education on critical components of the intervention, customizing game play, teaching use of the technology, establishing
the treatment contract, and performing guided problemsolving to address barriers to arm use. Subsequent sessions
are one-hour and involve review of transfer package elements and guided problem-solving to promote increased
affected arm use for daily activities.
Group 3: In-home gaming CI therapy + online therapist
consultation

Treatment intervention for Group 3 is identical to Group
2, with the addition of supplemental videoconferencing
with therapists. Group 3 participants receive video consultation sessions on the 6 treatment days that in-person therapist consultation does not occur (to equate the number of
therapist consultation sessions between Group 1 and
Group 3). The first video consultation session (day 2) is 1 h
in length and each subsequent video consultation session
(days 4, 6, 7, 9, 10) is 20 min for a total of 4 additional
hours of teleconsultation. The Health Insurance Portability
and Accountability Act (HIPAA) compliant videoconference program Bluejeans is utilized to facilitate secure
communication for Group 3 teleconsultation. Ten total
therapist encounters occur, equating total therapist encounters with that of traditional in-clinic CI therapy
(Group 1). Video consultation sessions focus on review of
transfer package elements and guided problem-solving to
promote increased affected arm use for daily activities.
Protocol adherence is reviewed and additional problemsolving is employed to improve compliance when needed.
As with Group 1, the MAL in follow-up with guided
problem-solving is administered via phone for 4 weeks
post-intervention.
Group 4: In-clinic standard upper extremity rehabilitation

Group 4 completes five hours of in-clinic standard upper extremity rehabilitation over four sessions (same in-clinic
schedule as Group 2). The intervention incorporates activities that are typically used in clinical rehabilitation settings.
The standard care protocol was established to standardize
“traditional care” based on responses from several practicing
physical and occupational therapists regarding activities that
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they would incorporate into the care of individuals with
mild/moderate upper extremity hemiparesis. The approach
combines neuromuscular reeducation, functional training,
progressive strengthening, and teaching/review of home
programming. This protocol consists of 25 min of evaluation, 50 min of neuromuscular reeducation, 100 min of
functional training, 70 min of progressive strengthening,
and 55 min of teaching/reviewing home programming over
the course of 4 sessions.
The relative time allocated to each activity reflects an
average of the responses provided by the therapists.
Following a 25 min evaluation on Day 1, the following
components of the intervention are delivered: 1) neuromuscular re-education (20 min on Day 1, 10 min daily
thereafter), 2) functional training (25 min all treatment
days), 3) progressive strengthening (25 min on Day 1,
15 min thereafter), and 4) review/adjustment/teaching of
home program (25 min on Day 1, 10 min thereafter). The
activities incorporated into the treatment are designed to
meet the specific needs of the participant (e.g., work to improve their body structure challenges, activity limitations,
and participation goals). The protocol is standardized regarding activity categories, activity selection, activity intensity target level, and progression principles. It is expected
that several trials of a given activity category are accomplished during specified time frames; it is expected that the
number of trials may vary between participants based on
their movement and endurance capabilities.
For the active procedures of neuromuscular reeducation, functional training, and progressive strengthening, the target for exercise intensity is 4 (somewhat
hard) on the Borg CR10 Rating of Perceived Exertion
Scale (Table 3 below). Therapists work with the patient
to ensure that activities are conducted with high quality
and grade the difficulty of the activity so that the participant is consistently working at a level 4 on the Borg
CR10 Rating of Exertion Scale. In subsequent visits,
Table 3 Borg CR10 Rating of Perceived Exertion Scale
Classification

Descriptor

0

Nothing at all

0.5

Very, very light

1

Very light

2

Fairly light

3

Moderate

4

Somewhat hard

5

Hard

6

-

7

Very Hard

8

-

9

-

10

Very, very hard (maximum)

Gauthier et al. BMC Neurology (2017) 17:109

therapists adjust the activity grade (up or down) to
achieve exertion of level 4 of the Borg CR10 Scale.
A home program is designed for all participants on
the first visit. This home program consists of TheraBand strengthening exercises to be done over a
15 min time period twice daily (total of 30 min daily)
for the first 10 days that they are not receiving inclinic therapy. Therapists design this program based
on the participant’s skill with the exercises and the
appropriate level of exertion (4 on the Borg CR10
Scale). During subsequent clinic visits (i.e., visits 2–4),
therapists provide written instructions for exercises
and review and modify the exercise program, as appropriate. Therapists may, at their discretion, give
general recommendations for Group 4 clients to use
the more affected arm outside of therapy (e.g., “try to
use your weaker side more for dressing”). They will
not engage the client in guided problem-solving or CI
therapy transfer package activities (e.g., examining a
client’s daily routine in detail), as these interventions
are not typically utilized during standard care. The
way in which therapists promote carry-over in Group
4 is thus much less specific/focused, less patientcentered, and less task-oriented than in Groups 1–3.
After 6 month follow-up testing, participants in Group
4 cross-over to a gaming condition that is identical to
Group 2, except they will only receive a single 2-h consultation with a therapist instructing them on use of the
system and educating them on transfer package components. This crossover design is ethically responsible and
will enable the team to test the feasibility and initial efficacy of a stand-alone implementation of in-home gaming CI therapy, as well as to determine the effect of
varying amounts of therapist contact on game-based rehabilitation outcomes [2 h (Group 4 crossed over) versus
5 h (Group 2) versus 9 h (Group 3)].

Relevant group comparisons

The clinic-based CI therapy arm is the standard against
which video game-based CI therapy will be compared
(Group 1 versus Groups 2 and 3). Comparison between
Groups 1 and 2 controls for time spent in active motor
practice between in-clinic versus gaming CI therapy modalities. Comparison between Groups 1 and 3 controls
for the number of encounters with a physical therapist
between in-clinic versus gaming CI therapy. Comparison
between Group 4 cross-over, Group 2, and Group 3 will
determine the extent to which therapist contact influences treatment response of a home-based intervention.
Comparison between Groups 2 and 4 will demonstrate
whether game-based treatment between therapy sessions
enhances motor outcomes, controlling for total face-toface time with a physical therapist. All treatment
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materials relevant to each group can be accessed open
source on the PI’s ResearchGate account.
Hypotheses

We hypothesize that Groups 1–3 will not differ in response to treatment and that this response will be superior to that of Group 4 on both the MAL and the WMFT.
We also anticipate that Groups 1–3 will show better retention of treatment gains than Group 4.
Standardization of intervention

To ensure data quality and consistent administration of
interventions across study arms and among all therapists,
extensive training is conducted with interventionists. All
sites received in-person training in the study procedures
by Lynne V. Gauthier, Ph.D. (PI) and Alexandra Borstad,
Ph.D., PT, NCS (Co-I). Additional training is provided as
needed. Standardized checklists and treatment forms are
utilized to ensure consistent documentation and to guide
the therapist in adhering to the protocol.
To ensure fidelity of each intervention and reduce
protocol drift, treatments are video recorded. Due to the
extensive treatment time for Group 1, only select portions
of this treatment will be recorded (days 1, 2, 6, and 10).
These recorded sections include 2 shaping tasks and the
entirety of the transfer package. Video recording instructions and listing of specified recording activities can be
viewed on ResearchGate. A randomly selected subsample
of recordings is reviewed by an independent rater for adherence to protocol. Therapists are periodically informed
of their adherence and the PI is notified of any instances
in which retraining is required. Relative time spent on
each element of the intervention is logged in the project
database, along with the name of the treating therapist.
Although some variation is to be expected based on the
individual needs of the client (e.g., one client may require
longer to master game play than another), if systematic
variations or <90% adherence to study protocol is observed for a particular therapist, that therapist receives
personalized retraining. Persistent noncompliance by staff
will be addressed by retraining and additional monitoring.
If retraining is unsuccessful, noncompliance may result in
termination. Noncompliance by staff that places participants at risk (e.g., violation of confidentiality) may be addressed by termination of staff. Noncompliance by
investigators or staff will be reported to the Institutional
Review Board (IRB).
Participant compliance with in-home portions of the
study interventions is objectively recorded whenever possible. For example, an accelerometer device within the restraint mitt (Group 1) tracks wear time. Participants and
their caregivers record compliance with use of the restraint mitt to cross-reference with the objective recordings or in case of technical failure. Game play data and
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computerized MAL administrations are stored both locally and on a cloud-based server with timestamp information that enables precise calculation of active play time.
Use of the smart watch biofeedback device and performance of home-practice tasks is logged by the participant
on study forms. Participant adherence to each element of
the protocol is documented.

to compare the results of the proposed trial. The WMFT is
listed as a primary outcome measure during the treatment
phase, but as an exploratory outcome in follow-up due to
limitations in capturing this measure remotely should attrition be problematic (e.g. participants moving away, losing
transportation, etc.).
Exploratory outcome measures

Outcomes

There are three evaluation points in this study protocol:
pre-treatment, post-treatment, and 6-months posttreatment. Individuals randomized to Group 4 complete
additional post-treatment testing after they complete the
crossover treatment condition (see Table 5). Table 4 lists
the measures administered throughout the course of the
study. The primary endpoint is immediately posttreatment (effectiveness of intervention). Six-month
follow-up is considered as a secondary endpoint, as retention is likely more strongly influenced by factors outside of the experimental protocol (e.g., interim care).
Primary outcome measures

Qualitative analysis of feedback from our Advisory Board
indicated two main therapy objectives: 1) regaining sufficient motor control to accomplish daily tasks/hobbies independently (using both hands) and 2) decreasing the
time/effort required to perform tasks.
To address the former, quality of arm use for daily activities is measured via the (MAL, which is a reliable and valid
measure of quality of movement and arm use in individuals
with subacute stroke [45]). To address stakeholders’ priority of increased speed of movement, the WMFT measures
the time to complete standardized functional movements
[42, 46–48]. It has established reliability and validity [42,
46–48] and has been commonly employed in previous CI
therapy trials [5, 19, 37], providing a metric against which

Secondary/exploratory outcome measures are measures
which a) have yet to be validated (e.g., kinematic data obtained from new wearable sensors) or whose psychometric
properties are still being established (e.g., Neuro-QOL), b)
measure constructs that may impact response to the therapy (e.g., sensation, cognition), c) may be less sensitive to
treatment change (e.g. 9-Hole Peg Test) [49], or d) measure potential moderating factors such as compliance.
The Quality of Life in Neurological Disorders (NeuroQOL) assessment is a validated computerized adaptive
self-report measure of health-related quality of life for
individuals with neurological disorders. It assesses aspects of physical, cognitive, emotional, and social functioning that are important to stakeholders and was
developed using patient-centered methods [50–52].
Wearable sensors quantify both arm use and kinematics
of arm movement throughout participants’ daily activities.
These sensors are worn bilaterally on the wrists and upper
arms, as well as on the chest. They quantify arm position
using integrated accelerometer, gyroscope, and magnetometer sensors. Participants are instructed to wear their
activity monitors on both arms for two days prior to treatment initiation in order to establish a baseline measure of
arm use. They wear the activity monitor every day during
the intervention phase of treatment. Data from these devices has not yet been clinically validated; the current
study plans to examine the utility of this objective data as
an exploratory analysis given the strong need for reliable,

Table 4 Testing measures collected at each time point
Datum

Primary

Motion Capture via wearable sensors
Motor Activity Log (MAL)

Secondary

Addresses

Pre

Post

6mo

X

Nonuse for daily activities

X

X

X

Nonuse for daily activities

X

X

X

X
a

WMFT Performance Time

X

Motor Speed

X

X

Xb

Grip strength of WMFT

Xa

Weakness

X

X

Xb

Quality of Life

X

X

X

Kinematics during game play
Neuro-QOL

X
X

ROM, motor control, ataxia, precision, speed

X

Brief Kinesthesia Test (BKT)

X

Sensory proprioception

X

X

Xb

Touch Test Monofilaments

X

Tactile sensation

X

X

Xb

9-Hole Peg Test

X

Dexterity

X

X

Xb

Montreal Cognitive Assessment (MoCA)

X

Cognitive Screen

X

Satisfaction Questionnaire

X

Satisfaction with treatment received

a

WMFT is primary outcome measure for pre- and post-testing but is a secondary outcome measure at 6-month follow up.
b
If participant is able to be physically present for administration.

X

Gauthier et al. BMC Neurology (2017) 17:109

objective measures of daily arm use. Angles of the shoulder, elbow, and trunk can be derived from sensor outputs.
Additionally, kinematic data collected during game play
(participants in Groups 2 and 3) will be similarly examined. These data provide x,y,z coordinates of Kinect skeletal joints. Kinematic metrics that can be examined from
both sets of data include speed of movement, smoothness
of movement, and range of motion. One range of motion
metric particularly relevant to stakeholders is Kinematic
Reaching Volume, defined as the percentage of space that
an individual accesses (convex hull of observed movements) relative to the volume that could be accessed if full
range of motion were present.
The Brief Kinesthesia Test (BKT) quantifies error in
targeted reaching to evaluate kinesthetic impairment
[53]. It can sensitively detect differences in kinesthetic
sense between people with mild-moderate hemiparesis
post-stroke and age-matched controls [54].
Touch Test™ monofilament aesthesiometer quantifies
the threshold of index finger touch perception in grams
[55] with acceptable interrater reliability (ICC = .77–.99)
[56] and test-retest reliability (ICC = .69–.71) [57].
Touch test data will be log transformed as recommended for normalization [58].
To enable examining individual factors associated with
treatment response (secondary objective), the following
demographic variables and treatment related factors will
be collected: gender, race/ethnicity, premorbid handedness
(self-report), rural/urban status according to census data
[59], gross cognitive ability via the Montreal Cognitive Assessment [60–62], total hours of mitt use (Group 1), total
hours of game play (Groups 2 and 3), number of computerized MAL administrations (Groups 2 and 3), and number of repetitions. Number of repetitions will be measured
via therapist logging for Group 1, video review for Group
4, and in-game logging for Groups 2 and 3. In-game
movements are defined as identified gestures that yielded
an in-game action (e.g., moved the kayak forward).
Standardization of assessments

Project testers undergo extensive training on the measures
by an experienced tester prior to testing any participants.
They complete two video-taped testing sessions to enable
their intra-rater reliability to be established. During these
testing sessions, an experienced tester will also rate “participant” performance to enable establishing inter-rater agreement. If agreement is less than excellent (e.g., discrepancies
of >.3 on individual WMFT performance time item scores),
additional training is required. All testing sessions will be
video-recorded for later reference and fidelity review.
Participant timeline

Four centers will randomize 224 individuals. Enrollment
began March 2016. The first baseline assessments were
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conducted during the third week of March 2016. Anticipated duration of data collection will be 2.5 years. Participation will occur over six months for individuals
randomized to Groups 1–3. Individuals in Group 4 participate for approximately seven months.
An initial phone screening is often conducted to screen
for potential eligibility. Participants deemed potentially eligible for the study based on the phone screening complete
an in-person screening at their respective clinical site. Eligible individuals who have provided informed consent will
be randomized. Enrollment is defined as having signed the
Informed Consent document. Prospective participants
who express interest are scheduled to complete screening
with their respective site coordinator. Methods of recruitment are described below.
Participants deemed eligible to participate following
initial screening (see In Person Screening Form on
ResearchGate) are stratified into two functional groups
(higher and lower functioning) prior to randomization
(Fig. 2). Stratification is based on the participants’ ability
to place any number of pegs on the 9-Hole Peg Test
within 120 s. Individuals are classified as higherfunctioning if they can place any number of pegs (1–9)
within the allotted time. If unable to place any pegs, the
participant is classified as lower-functioning. Stratification serves to more equally distribute the initial motor
functioning of participants across groups. This is important because response to motor training depends, in part,
on the extent of dexterous function of the participant
[63, 64]. The sequence for randomization is represented
in Fig. 2. Table 5 outlines the study structure.
Sample size

A sample size was selected to provide 80% power to detect
a minimal clinically important difference (MCID) in improvement on the WMFT between traditional CI therapy
and therapist-as-consultant in-home gaming CI therapy.
According to Lin & co-authors [65], the MCID on the
WMFT is a 16% change. Taub and colleagues found that
subjects undergoing traditional CI therapy exhibited an
average improvement of 20.5% from pre-test to post-test
on the WMFT [13]. A power analysis, using a Monte
Carlo approach, indicated that 51 subjects would be sufficient. The analysis was based on the data from a previous
study [13] and used a two-sided test and an alpha level of
0.05. The CI therapy literature shows that the effect size
for changes in real-world arm use is approximately three
times larger than the effect size for changes in WMFT
score [13]. This suggests that a study that is adequately
powered to detect minimally clinically significant changes
in the WMFT will also be sufficiently powered to detect
changes on the MAL. Accounting for an estimated
10% attrition, we anticipate enrolling 224 subjects
into the study among the four sites.
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Fig. 2 Schematic illustrating the randomization process

Recruitment

Assignment of interventions

Prospective participants will be identified largely through
mining electronic medical records for ICD-9 and ICD-10
codes that indicate potential eligibility (Table 5). Potentially
eligible individuals will then be sent a direct mailing via
United States Postal Service with an informational brochure
and contact information for their local study representative.
Recruitment will also target community groups, the general
clientele of outpatient clinics, discharge materials on inpatient rehabilitation units, and relevant community organizations. This recruitment approach attempts to reduce
selection bias through active pursuit rather than passive acceptance of highly motivated participants already actively
seeking participation in research studies.

Sequence Generation and Allocation Concealment
Mechanism: Each site will keep two separate large envelopes, one for the low functioning group and one for the
high functioning group. There will initially be 3 sets of
each group number (1, 2, 3, 4) in each envelope. The
group numbers are sealed (e.g., written on folded over
sticky notes or within small sealed envelopes) such that
participants (as well as research coordinators) are unable
to see the numbers when participants are self-selecting a
group. Low functioning participants will choose a number from the “low” envelope and higher functioning participants will chose a number from the “high” envelope.
The number selected will not be placed back into the

Table 5 Study Structure
STUDY ARM
Group 1
CI therapy (n = 51)

Pre-tx THERAPY
testing (Weeks 2–4)
Week 1
35 face-to-face hours

Group 2
CI therapy gaming
(n = 51)

5 face-to-face hours in clinic, 15 h in-home
gaming

Group 3
Telerehab
CI therapy gaming
(n = 51)

5 face-to-face hours in clinic, 4 face-to-face
hours via video conference, 15 h in-home
gaming

Group 4
Standard Upper
Extremity
Rehabilitation
(n = 51)

5 face-to-face hours

Post-tx 6 month
testing follow-up
Week 5 testing

THERAPY
(Group 4 only; crossover for 3 weeks)

2 h consultation in clinic, 15 h in-home
gaming followed by post-treatment
testing
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envelope. When there are 5 numbers left in an envelope,
2 more of each number will be added by the research
coordinator prior the randomization of the next participant. This will ensure complete randomization of all
participants, while enhancing probability of evenly balanced group sizes.
Implementation

Randomization is overseen by each site’s research coordinator. Participants self-select a sealed group allocation from
the envelope.
Blinding

Tester(s) are blinded to participant group assignments. Participants, interventionists, and study administrators have
access to study group information. Participants are
instructed not to disclose any aspects of their treatment to
the tester in order to maintain blinding.
Data collection & management
Data collection

Data collection forms specific to this study can be found
on the PI’s ResearchGate account.
To enhance participant retention, a financial incentive
of $50 per occasion is given for attending testing sessions.
A thank-you mailing is sent to participants a month after
study completion with reminder of their follow-up testing
date. Additionally, members of the Advisory Board suggested the following compliance-enhancing measures to
be employed in this trial: 1) frequent feedback regarding
adherence, 2) reminder phone-calls (to attend in-person
therapy, complete scheduled at-home game play, and perform home exercises), 3) providing an instructional DVD
for the client and family (e.g., to educate/inform family
members about CI therapy), and 4) being provided with a
T-shirt at study completion if >90% adherence was
achieved. Inevitable disruptions (e.g., due to illness) of up
to 5 treatment days will be permitted and treatment extended accordingly until all treatment sessions have been
completed.
Data management

All non-electronic data (e.g., signed consent forms, hard
copies of assessment forms) are stored in a secure, locked
filing cabinet behind a locked door at each study site.
Testing data are entered into a secure (and backed up)
REDCap [http://projectredcap.org] database within 48
business hours of data collection. Electronic data are collected from the motion capture wearable devices, the
gaming system, and NeuroQOL computerized adaptive
assessment. All electronic data are stored in an electronic
repository behind The Ohio State University Medical Center’s firewall according to participant ID#. Video data are
sent from study sites to The Ohio State University (OSU)
via encrypted USB storage drives. Identified (coded) study
records are retained until analysis is completed on the
project. All electronic data is stored in REDCap for a
minimum of seven years after study completion. After
publication of research findings, de-identified records will
be published open-source on ResearchGate.
Pre-, post-, and 6-month follow up testing appointments
are scheduled by the research coordinator at the time of
intervention scheduling. Data to be collected includes potential adverse events, sensorimotor outcome measures,
and client satisfaction questionnaire (see Table 6 below).

Data collection and accurate documentation are the responsibility of study staff under the supervision of the PI.
All study documentation is reviewed by the data entry
staff, ensuring that they are accurate and complete.
Checklists are utilized to minimize missing data resulting
from improper staff procedure.
Quality control procedures

Participant game-play actions are logged. The game records the x-y-z coordinates of each skeletal joint (skeletal
data). It also records gestures and game actions that were
detected, each with time-stamps that can be used to determine total play time. MAL and problem-solving responses
are also recorded. These data are stored locally until it is
periodically pushed to a cloud server. A report is automatically generated from these files, including MAL scores
and active play times. This report is accessed by the therapist during consultation visits to trouble-shoot barriers to
adherence if needed.
Data entry is performed by Research Assistants (RAs) at
OSU. Data entry errors are minimized by training data
entry personnel on how to administer the outcome measures. Data entry personnel also review the dataset for

Table 6 ICD-9 and ICD-10 codes describing hemiplegia/monoplegia secondary to stroke
Diagnosis

ICD-9 Code

ICD-10 Code

Cerebral Infarction, unspecified

434.91

I63.9

Hemiparesis/hemiplegia

342.90, 438.20–22

G81.90, I69.359, I69.351, I69.354, I69.159

Monoparesis/monoplegia

344.40, 344.5

G83.30–34, G83.20–24, I69.939

Flaccid hemiparesis/hemiplegia

342.00–02

G81.00

Spastic hemiparesis/hemiplegia

342.10–12

G81.10–14

Monoplegia of upper limb

344.40–42

G83.20–24
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outliers and improbable values every 3 months to identify
possible data entry errors. If aberrant values are observed,
these are cross-referenced with the original forms and
video-taped testing sessions as necessary. Neatness of documentation is stressed to the testers to ensure that forms are
easily legible to those who are entering data. Paper forms
are scanned and stored on the secure backup server for
easy access by any member of the OSU project staff.
Statistical methods
Aim 1

Compare the effectiveness of two technology-based models
of in-home CI therapy versus traditional clinic-based CI
therapy versus standard upper extremity rehabilitation
for improving upper extremity motor function. Therapyinduced changes in performance speed (WMFT), realworld arm use (MAL), and quality of life (NeuroQOL)
will be analyzed via mixed effects linear models. Initially,
separate models will be constructed for the three primary
outcome measures. Each of these models will include treatment and time (as well as their interaction) as fixed effects
and participant as a random effect. In these models, the
interaction of treatment and time is the primary effect of
interest, since it tests the difference in change over time
among the four treatment groups. The response variables
will be transformed to a natural log scale before model fitting to aid in interpretation such that the coefficient associated with the time effect within a treatment can easily be
interpreted as a percentage change in the outcome variable. Demographic measures and initial scores on outcome
variables will be compared between groups using t-tests,
non-parametric analogues such as Mann-Whitney U, or
chi-squared tests. Significant differences will be considered
in interpretation of the results. Results will be reported according to the CONSORT guidelines.
Aim 2

The secondary objective of this project is to promote personalized medicine by examining individual factors that
may differentially influence response to one treatment
versus another. The following potential factors will be examined for each of the primary outcome variables: mild/
moderate versus moderate motor dysfunction (based on
ability to place 1 or more pegs on the 9-hole Peg Test at
pre-treatment), number of repetitions performed, therapy
adherence, tactile sense (Touch Test Monofilaments), proprioceptive ability at baseline (Brief Kinesthesia Test),
Kinematic functional reaching volume, cognition (MoCA),
PHQ-9 depression score, age, gender, chronicity, and
whether or not the dominant hand was more affected.
Based on our pilot data (Borstad A, Crawfis R, Phillips K,
Pax Lowes L, Worthen-Chaudhari L, Maung D, et al.: Inhome delivery of constraint induced movement therapy
via virtual reality gaming is safe and feasible: a pilot study,

Page 14 of 18

submitted) and data from Taub and colleagues [13], we
hypothesize that treatment-induced improvements on our
primary outcome variables will be unrelated to the majority of these variables, with the exception of initial motor
ability (preserved pinch grasp) [53]. Higher initial motor
ability has been associated with 25% and 200% greater improvements in arm use (UAB Traditional CI therapy/
OSU Gaming CI therapy cohorts, respectively), and 25%
lesser improvement on the WMFT (both cohorts) [63]. A
confirmatory analysis of this hypothesis will be conducted
by adding baseline motor ability as a fixed effect to the
original mixed effects general linear model. Other exploratory variables will be added to the model in a stepwise
manner. Dummy coded contrasts will be utilized for the
categorical variables of initial motor ability. Of interest is
the extent to which each factor enhances predictive value
of the overall model, the interaction of the factor with
time, and the 3-way interaction between factor, time, and
group. If 3-way interactions are observed, post-hoc tests
will be carried out to determine the differential influence
of the factor on one treatment versus another, controlling
for family-wise error utilizing the Holm method.

Missing data

Intent-to-treat analysis will be carried out. In these analyses,
data from participants who voluntarily withdraw from treatment, those with poor compliance, and those unable to tolerate the treatment protocol (e.g., increased pain in trained
upper extremity) will be included. Pre-treatment scores will
be carried over for participants who voluntarily withdraw
from the study (conservatively simulating no change pretreatment to post-treatment). Data from participants who
must withdraw for reasons unrelated to the study (e.g., medical issues unrelated to the study) will be removed from analysis via list-wise deletion and will not be included in the
intent-to-treat analysis. The mixed effects model planned
for analysis is purely likelihood-based and can make use of
all of the data available with no necessary modifications for
differing numbers of subjects at each time point.
Data from participants lost to follow-up (those who
did not complete 6 month assessment) will be imputed via multivariate analysis of prognostic factors.
Follow-up data loss is minimized by having primary
outcome measures that can be remotely administered
when necessary (MAL, NeuroQoL). Missing data will
be dummy coded within the general linear model to
determine whether data is likely missing completely
at random, missing at random, or missing not at random. Alternative methods for addressing missing data
will be examined (e.g. maximum likelihood, multiple
imputation). Statistical testing will be used to determine whether individuals lost to follow-up differ from
those who completed the study.
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Monitoring
Data monitoring

The OSU Center for Clinical and Translational Sciences
(CCTS) Research Informatics Services Core is used as a
central location for data processing and management of
electronic data. Electronic data are stored in REDCap
for a minimum of seven years after study completion.
The provisioning of accounts and user access to specific
database(s) is integrated with the OSU Medical Center
authentication service for studies containing protected
health information (PHI), and the provisioning of access
and specific user rights for all studies are managed by
CCTS staff. Data safety monitoring is being provided by
individuals with appointments at The Ohio State University who have no intellectual/financial stake in the study
and who are not otherwise affiliated with the study (independent safety officers). Monthly meetings are
planned between project staff and independent safety officers. These individuals also provide determination of
severity of adverse events as needed and prompt reporting to IRB.
Harms

The Department of Health and Human Services (HHS)
Office for Human Research Protections (OHRP) defines
unanticipated problems (UP) and adverse events (AE)
[66], these definitions are utilized for protection of subjects in the current study. The PI reviews information
relevant to the safety of the subjects and the integrity of
the data on a monthly basis.
Reporting procedures

Therapists administering the interventions assess for adverse events at each clinic visit and report to the site PI,
study PI, and the independent safety officer immediately
if any adverse event(s) should occur. All reported adverse events are recorded on the Adverse Event Reporting Form (see form on ResearchGate).
To satisfy the requirement for prompt reporting, unanticipated problems are reported using the following
timeline:
 Unanticipated problems that are serious adverse

events are reported to the IRB within 48 h of the
investigator becoming aware of the event.
 Any other unanticipated problem is reported to the
IRB within 2 weeks of the investigator becoming
aware of the problem if the problem is study-related.
 All other events are reported to the IRB during
annual review.
Complaints made by research participants indicating
unanticipated risks, participant complaints that cannot be
resolved by the research staff, and unapproved changes
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made to the research to eliminate an apparent immediate
hazard to a research participant are also promptly reported. Events related to the research that do not meet
the prompt reporting requirements are reported at the
time of the continuing review.
Auditing

Study staff will permit authorized representatives of
PCORI and regulatory agencies to examine (and when
required by applicable law, to copy) research records for
the purposes of quality assurance (QA) reviews, audits,
and evaluation of the study safety, progress and data validity. Additionally, Institutional Review Boards at each
study site may at any time initiate an audit.
Dissemination

The proposed dissemination plan will be further refined
during quarterly meetings with the Advisory Board. Board
members will participate in generating additional ideas for
methods of dissemination. Initial ideas established collaboratively between the Board and academic team include
the following: presenting at local support groups, harnessing social media, generating the interest of TV and radio
media outlets, and drafting a lay publication to be submitted to StrokeSmart, the publication of the National Stroke
Association. To ensure that results are communicated
most effectively to the community, members of the Stroke
Advisory Board and Co-I Strahl will direct the dissemination activities and will participate in drafting the publication. Select members of the Board have also expressed
their enthusiasm with working with the media to share
their experiences (and some have already done so).
To increase therapist ownership of this new treatment
and to enhance dissemination, we have incorporated community therapists as Advisory Panel Members/Co Investigators on the project. These individuals will provide a
valuable perspective regarding how to present these results most effectively to the therapist community. Therapists at the Providence site will also gain practical
experience in utilizing this intervention within a rural
clinic setting. This site is representative of clinics that
serve those (rural) clients who may benefit most from the
model of therapy employed here. Therapist stakeholders
have indicated their willingness to make the therapist
community aware of this new intervention at Continuing
Education conferences and through routine clinical
interaction.

Discussion
Motor interventions, such as CI therapy, that include both
intensity of training and techniques to enhance carry-over
have been shown to enhance post-stroke outcomes and
promote brain plasticity [7, 13, 14]. Yet, less intense and
less effective approaches are most frequently utilized in
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clinical care [4]. Moreover, multiple access barriers to
quality care exist [32, 67]. The results of this RCT will
provide a significant addition to our body of knowledge
regarding the potential for functional motor improvement
of upper extremity hemiparesis following stroke. Specifically, they will determine whether using technology can address primary access barriers to quality care, including
difficulty of travel for in-person therapy, expense, scheduling demands, and dearth of trained CI therapy providers.
Moreover, if effective, a remotely-delivered model of care
may facilitate patient choice of providers or clinics (e.g. a
client may seek a treatment provider who is located far
from their home).
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conducted in full conformity with the principles set forth in The Belmont
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Participants of Research, as drafted by the US National Commission for the
Protection of Human Participants of Biomedical and Behavioral Research
(April 18, 1979) and codified in 45 CFR Part 46 and/or the ICH E6 [22]. The
protocol, informed consent form(s) (ICF), recruitment materials, and all
participant materials have been approved by the IRB’s at each site. OSU
serves as IRB of Record for OhioHealth and PMMC.
Protocol Amendments: Any amendment to the protocol requires review and
approval by the relevant IRB before changes are implemented in the study.
No substantive changes to study procedures will be made to this protocol
except if necessary to ensure participant safety.
Consent Process: Informed consent is a process that is initiated prior to the
individual agreeing to participate in the study and continues throughout
study participation. Extensive discussion of risks and possible benefits of
study participation is conducted with participants and their families. An IRBapproved consent form describing in detail the study procedures and risks is
given to the participant. The investigator or designee explains the research
study to the participant in detail and answers any questions that arise. The
participant is required to demonstrate understanding of the study
procedures, risks, and benefits using available communication strategies. This
may be accomplished by having the participant “teach back” to the
investigator. If expressive aphasia is present, understanding can be demonstrated through use of gesture, response to yes/no questions (e.g., “Do you
get to pick your study group?”), or modeling of activity. The participant (or
designated proxy) signs the informed consent document prior to any studyrelated assessments or procedures. Participants are given the opportunity to
discuss the study with their support person(s) and are offered the option of
delayed consent if they wish to further contemplate whether or not to
participate. Participants are informed that they may withdraw consent
without penalty at any time. A copy of the signed informed consent
document is offered to participants for their records. The rights and welfare
of the participants are protected by emphasizing to them that the quality of
their clinical care will not be adversely affected if they decline to participate
in this study. The consent process is documented in the research record.
Confidentiality: Data being analyzed are exported in de-identified format.
Identities of participants will not be revealed in the presentation or
publication of any result from this project. Assistants & others working on
this project are educated about the importance of strictly protecting
subjects’ rights to confidentiality. Participants will be informed in the event
of law-mandated instances in which confidentially could have been or was
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Access to Data: Study personnel at The Ohio State University and University
of Alabama at Birmingham will have access to the final study data set.
Ancillary and Post-Trial Care: No provisions or compensation can be provided
for those who may suffer harm from trial participation. This is made clear
during the consent process.
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